|
||
| |||||||
|
The Cardiovascular Market Outlook to 2009 Identify which cardiovascular indications are forecast to show the highest levels of market potential in the forecast period 2004 - 2009 with this latest report… The NEW Reuters Business Insight management report The Cardiovascular Market Outlook to 2009 provides detailed analysis on the major cardiovascular therapy areas and assesses competitive dynamics over the period 2004 to 2009. This report provides essential data, analysis and forecasts to 2009 allowing you to position your products effectively, maximize market opportunities and increase cardiovascular revenues. Building
on the success of last years report, this 2004 edition will provide you with... · Drug profiles and competitor analysis of 13 major potential future cardiovascular blockbuster drugs. · Patient potential of 13 cardiovascular markets. · Marketed products, R&D compounds and cardiovascular portfolio sales forecasts of 6 leading companies including; Pfizer, Merck & Co, Bristol-Myers Squibb, Novartis, AstraZeneca, Aventis. The cardiovascular market is set to undergo a period of radical change, as today's blockbusters lose patent protection. The pharmaceutical industry is embracing innovative new technologies in order to provide the products of tomorrow, but with high costs and risks associated with the development of new medicines in this area, there will be fewer winners than losers in the future. Use this analysis to identify the forthcoming issues affecting cardiovascular markets, drugs, and companies and gain insight into the forces driving the most valuable sector of the pharmaceutical industry over the next 5 years.Oct 2004 142 pages PDF Format Click title to order: The Cardiovascular Market Outlook to 2009 To order these reports contact peter.barfoot@bioportfolio.com or telephone +44 1300 321501 or +1 415 680 2472 and a representative will get back to you. You can also order on line at: http://www.bioportfolio.com/cgi-bin/acatalog/search.html
|
|
| ||||||||